Dr. Burstein on the Follow-Up of APT Trial for HER2+ Breast Cancer
Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the 7-year follow-up of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.
Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the 7-year follow-up of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.
In the initial results, there was a disease-free survival of 97%, explains Burstein. Those results were validated following the 7-year follow-up. Additionally, the instance of distant metastatic recurrence is low.
These follow-up results demonstrate that the patients on this trial have seen significant benefits, states Burstein.
